Caffeine use in the neonatal intensive care unit.

Area of Science:

• Neonatal Medicine
• Pharmacology
• Developmental Pediatrics

Background:

• Caffeine is a common medication in neonatal intensive care units (NICUs).
• It is primarily used for apnea of prematurity, with potential benefits for bronchopulmonary dysplasia (BPD) and patent ductus arteriosus (PDA).
• Long-term outcomes, including neurodevelopmental effects, require further investigation.

Purpose of the Study:

• To evaluate the efficacy and safety of caffeine in neonatal care.
• To assess the impact of caffeine on respiratory outcomes, survival, and neurodevelopmental trajectories.
• To explore the potential mechanisms of action for caffeine's observed effects.

Main Methods:

• Review of long-term studies on caffeine use in neonates.
• Analysis of data on incidence of BPD, PDA, and survival rates.
• Assessment of neurodevelopmental outcomes at various follow-up points (18-21 months and 5 years).

Main Results:

• Caffeine use is associated with reduced incidence of BPD and PDA, and improved survival.
• Sustained improvements in coordination and reduced gross motor impairment were observed at age 5.
• Neurodevelopmental advantages were not statistically significant at 5 years, but motor improvements persisted.

Conclusions:

• Caffeine is a safe and effective medication for neonatal apnea with potential benefits for BPD and neurodevelopment.
• Mechanisms may involve adenosine receptor inhibition, anti-inflammatory effects, white matter protection, and surfactant induction.
• Further research is needed to optimize caffeine dosing and treatment duration.